You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金城醫藥(300233.SZ)與慧澤生物簽署戰略合作協議
格隆匯 06-24 16:24

格隆匯 6 月 24日丨金城醫藥(300233.SZ)公佈,近日,公司與湖南慧澤生物醫藥科技有限公司(“慧澤生物”)簽署《戰略合作框架協議》,雙方本着平等協商、優勢互補、合作共贏的原則,就藥物研發技術服務締結長期戰略層面的CDMO合作伙伴關係。

慧澤生物是一家依據中國法律合法設立並有效存續的專注於藥物研發臨牀前以及I期臨牀試驗(含BE\PK)全過程專業服務的CRO公司,建設有製劑研究院、I期臨牀研究室和生物分析測試中心等體內外研發平台,擁有理論與實踐相結合的博士教授團隊和創新的體內外評價技術。

金城醫藥是一家依據中國法律合法設立並有效存續的創業板上市公司。公司主營業務以三、四代頭孢類醫藥中間體、特色原料藥、生物製藥、終端製劑以及婦兒產品的研發、生產、銷售為主。公司通過“實業+資本”雙輪驅動的發展模式,已構建形成獨具金城特色的製藥工業產業鏈。

雙方將積極致力於“藥物合成+藥物製劑+藥物臨牀”研究服務(“CRO服務”),以及“藥物生產”服務(“CMO服務”)之CDMO全產業鏈的合作,實行信息共享、業務聯動、功能互補,建立並不斷深化和鞏固背靠背的戰略合作伙伴關係,充分發揮各自優勢資源,共同做大做強。

此次公司與慧澤生物簽署《戰略合作框架協議》,符合公司長期發展戰略,有利於增強公司的藥物研發能力,提升藥品臨牀試驗能力。同時也有利於增強公司的持續盈利能力和整體抗風險能力,符合公司發展戰略及全體股東的利益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account